ITI-214市場：市場規模、予測、新たな洞察-2032年

Lenrispodun/ITI-214は、強力かつ選択的なホスホジエステラーゼ1型（PDE1）阻害剤であり、PDE1ポートフォリオのリード化合物です。ITI-214は、環状ヌクレオチド（cAMP、cGMP）の分解を阻害することにより、これらの分子が細胞内に蓄積し、重要な機能を発揮することを可能にします。

ITI-214は、臨床試験において良好な安全性プロファイルを示し、一般的に良好な忍容性を示しました。現在、ITI-214はパーキンソン病による運動機能変動患者を対象とした第II相試験で検討されており、また心不全の治療薬としても開発されています。

今後数年間で、パーキンソン病の市場シナリオは、世界中の広範な調査と医療費の増加により変化します。各社は、病状を治療/改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、ITI-214の優位性に影響を与える可能性のある機会を模索しています。パーキンソン病に対する他の新興製品は、ITI-214に厳しい市場競争を与えると予想され、近い将来、後発の新興治療薬が発売されれば、市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国におけるパーキンソン病治療薬のITI-214市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 パーキンソン病におけるITI-214の概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 ITI-214市場評価

• パーキンソン病におけるITI-214の市場見通し
• 主要7ヶ国分析
  • 主要7ヶ国のパーキンソン病治療薬ITI-214の市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: ITI-214, Clinical Trial Description, 2023
• Table 2: ITI-214, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Late-stage Emerging Therapies)
• Table 5: ITI-214 Market Size in the 7MM, in USD million (2019-2032)
• Table 6: ITI-214 Market Size in the US, in USD million (2019-2032)
• Table 7: ITI-214 Market Size in Germany, in USD million (2019-2032)
• Table 8: ITI-214 Market Size in France, in USD million (2019-2032)
• Table 9: ITI-214 Market Size in Italy, in USD million (2019-2032)
• Table 10: ITI-214 Market Size in Spain, in USD million (2019-2032)
• Table 11: ITI-214 Market Size in the UK, in USD million (2019-2032)
• Table 12: ITI-214 Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: ITI-214 Market Size in the 7MM, USD million (2019-2032)
• Figure 2: ITI-214 Market Size in the United States, USD million (2019-2032)
• Figure 3: ITI-214 Market Size in Germany, USD million (2019-2032)
• Figure 4: ITI-214 Market Size in France, USD million (2019-2032)
• Figure 5: ITI-214 Market Size in Italy, USD million (2019-2032)
• Figure 6: ITI-214 Market Size in Spain, USD million (2019-2032)
• Figure 7: ITI-214 Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: ITI-214 Market Size in Japan, USD million (2019-2032)

"ITI-214 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about ITI-214 for Parkinson's disease in the seven major markets. A detailed picture of the ITI-214 for Parkinson's Disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the ITI-214 for Parkinson's Disease. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ITI-214 market forecast analysis for Parkinson's disease in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Parkinson's disease.

Drug Summary:

Lenrispodun/ ITI-214 is a potent and selective phosphodiesterase type 1 (PDE1) Inhibitor and is the lead compound in the company's PDE1 portfolio. ITI-214 works by blocking the breakdown of cyclic nucleotides (cAMP, cGMP), thus allowing these molecules to build up in the cells and to exert important functions.

ITI-214 has been generally well tolerated with a favorable safety profile in clinical trials. Currently, ITI-214 is being investigated in a Phase II trial in patients with motor fluctuations due to Parkinson's disease and is also being developed for the treatment of heart failure.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the ITI-214 description, mechanism of action, dosage and administration, research and development activities in Parkinson's disease.
• Elaborated details on ITI-214 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ITI-214 research and development activities in Parkinson's disease across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around ITI-214.
• The report contains forecasted sales of ITI-214 for Parkinson's disease till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Parkinson's disease.
• The report also features the SWOT analysis with analyst views for ITI-214 in Parkinson's disease.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ITI-214 Analytical Perspective by DelveInsight

• In-depth ITI-214 Market Assessment

This report provides a detailed market assessment of ITI-214 for Parkinson's disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

• ITI-214 Clinical Assessment

The report provides the clinical trials information of ITI-214 for Parkinson's disease covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Parkinson's disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ITI-214 dominance.
• Other emerging products for Parkinson's disease are expected to give tough market competition to ITI-214 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ITI-214 in Parkinson's disease.
• Our in-depth analysis of the forecasted sales data of ITI-214 from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ITI-214 in Parkinson's disease.

Key Questions:

• What is the product type, route of administration and mechanism of action of ITI-214?
• What is the clinical trial status of the study related to ITI-214 in Parkinson's disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ITI-214 development?
• What are the key designations that have been granted to ITI-214 for Parkinson's disease?
• What is the forecasted market scenario of ITI-214 for Parkinson's disease?
• What are the forecasted sales of ITI-214 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to ITI-214 for Parkinson's disease?
• Which are the late-stage emerging therapies under development for the treatment of Parkinson's disease?

Table of Contents

1. Report Introduction

2. ITI-214 Overview in Parkinson's disease

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and Efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. ITI-214 Market Assessment

• 5.1. Market Outlook of ITI-214 in Parkinson's disease
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of ITI-214 in the 7MM for Parkinson's disease
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of ITI-214 in the United States for Parkinson's disease
  • 5.3.2. Market Size of ITI-214 in Germany for Parkinson's disease
  • 5.3.3. Market Size of ITI-214 in France for Parkinson's disease
  • 5.3.4. Market Size of ITI-214 in Italy for Parkinson's disease
  • 5.3.5. Market Size of ITI-214 in Spain for Parkinson's disease
  • 5.3.6. Market Size of ITI-214 in the United Kingdom for Parkinson's disease
  • 5.3.7. Market Size of ITI-214 in Japan for Parkinson's disease

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options